Core Viewpoint - The company Baotai expects to reduce its net loss for the fiscal year 2025 compared to the previous year, projecting a net profit attributable to the parent company of between -280 million yuan and -390 million yuan, which represents a reduction in loss of between 120.30 million yuan and 230.30 million yuan [1] Group 1 - The reduction in loss is attributed to the company's market expansion efforts [1] - Sales of Adalimumab and Tocilizumab have increased, contributing to the improved financial outlook [1] - The launch of Ustekinumab in the United States has also positively impacted revenue through licensing and sales growth [1]

Core Viewpoint - Baotai (688177) is expected to reduce its losses in 2025, projecting a net profit attributable to shareholders of between -280 million to -390 million yuan, a decrease in losses of 120 million to 230 million yuan compared to the previous year [1] Financial Performance - The company anticipates revenue between 900 million to 970 million yuan, an increase of 157 million to 227 million yuan compared to the same period last year [1] - The sales of Adalimumab injection (Geleli) and Tocilizumab injection (Shilili) have steadily increased compared to the previous year [1] Market Expansion - The launch of Ustekinumab injection (STARJEMZA) in the United States has contributed to growth in both licensing income and sales revenue [1]

北京商报讯（记者 王寅浩 宋雨盈）1月27日，百奥泰发布2025年业绩预告，预计2025年净亏损2.8亿— 3.9亿元，与上年同期相比，减少亏损1.2亿—2.3亿元。预计扣除非经常性损益后净亏损为3.8亿—4.9亿 元，将减少亏损6561.09万—1.76亿元。 ...

金马游乐：2025年净利润同比预增811.17%-1069.56% 1月27日晚，金马游乐(300756)发布业绩预告，预计2025年归属于上市公司股东的净利润为6700万-8600 万元，比上年同期增长811.17%-1069.56%。 诺德股份：对1.5万吨生产线进行技术改造 1月27日晚，诺德股份(600110)发布公告称，拟对全资子公司青海电子材料产业发展有限公司二厂1.5万 吨生产线设备实施更新改造，项目总投资估算为1.68亿元。改造完成后，生产线将具备4.5微米及以下高 端锂电铜箔的量产能力，以应对下游客户在高端产品领域的需求。 楚江新材：2025年净利润同比预增60.97%-95.78% 1月27日晚，楚江新材(002171)发布业绩预告，预计2025年归属于上市公司股东的净利润为3.70亿-4.50亿 元，比上年同期增长60.97%-95.78%。 八方股份：2025年净利润同比预增40.96%–72.29% 1月27日晚，八方股份(603489)发布业绩预告，预计2025年度实现归属于上市公司股东的净利润为9000 万元到1.1亿元，与上年同期相比，同比增长40.96%到72.29%。 艾森 ...

证券代码：688177 证券简称：百奥泰 百奥泰生物制药股份有限公司 2026年第一次临时股东会会议资料 2026 年 2 月 6 日 | II | 求 | | --- | --- | | 东会会议须知 | | | 2026 | 年第一次临时股东会会议议程 | 4 | | --- | --- | --- | | 2026 | 年第一次临时股东会议案 | 6 | 百奥泰生物制药股份有限公司 2026 年第一次临时股东会 百奥泰生物制药股份有限公司 二、为保证本次会议的严肃性和正常秩序，切实维护股东的合法权益，请出 席股东会的股东或其代理人或其他出席者准时到达会场签到确认参会资格。会议 开始后，会议登记应当终止，由会议主持人宣布现场出席会议的股东和代理人人 数及所持有的表决权数量。 三、会议按照会议通知上所列顺序审议、表决议案。 四、股东及股东代理人参加股东会依法享有发言权、质询权、表决权等权利。 股东及股东代理人参加股东会应认真履行其法定义务，不得侵犯公司和其他股东 及股东代理人的合法权益，不得扰乱股东会的正常秩序。 五、股东及股东代理人要求在股东会现场会议上发言的，应于股东会召开前 一天向会务组进行登记。会议 ...

本报告期公司业绩较上年同期将实现减亏。主要原因是公司营业收入为9亿元到9.7亿元，较上年同期增 加1.57亿元至2.27亿元。一方面公司积极拓展市场，阿达木单抗注射液(格乐立®)和托珠单抗注射液(施 瑞立®)销售额较上年同期稳步提升；另一方面本报告期公司乌司奴单抗注射液(STARJEMZA®)于美国 上市销售，授权许可收入及销售收入增长。 预计归属于母公司所有者扣除非经常性损益后的净利润为-3.8亿元到-4.9亿元，将减少亏损6561.09万元 至1.76亿元。 格隆汇1月27日丨百奥泰(688177.SH)公布，经财务部门初步测算，公司预计2025年度实现归属于母公司 所有者的净利润与上年同期相比，将减少亏损，实现归属于母公司所有者的净利润为-2.8亿元到-3.9亿 元，减少亏损1.20亿元到2.30亿元。 ...

Core Viewpoint - The company Baiotai (688177.SH) expects to reduce its losses in 2025 compared to the previous year, with projected net profit attributable to shareholders ranging from -280 million to -390 million yuan, a reduction in losses by 120 million to 230 million yuan [1] Financial Performance - The company anticipates a net profit attributable to shareholders, excluding non-recurring gains and losses, to be between -380 million and -490 million yuan, reducing losses by 65.61 million to 176 million yuan [1] - The expected operating revenue for the reporting period is between 900 million and 970 million yuan, an increase of 157 million to 227 million yuan compared to the same period last year [1] Market Expansion - The sales of Adalimumab injection (Geleli®) and Tocilizumab injection (Shiruili®) have steadily increased compared to the same period last year, contributing to the company's revenue growth [1] - The company has launched Ustinumab injection (STARJEMZA®) in the U.S., leading to growth in both licensing income and sales revenue [1]

人民财讯1月27日电，百奥泰(688177)1月27日公告，预计2025年度实现归属于母公司所有者的净利润 为-2.8亿元到-3.9亿元，同比减少亏损1.2亿元到2.3亿元。一方面公司积极拓展市场，阿达木单抗注射液 (格乐立)和托珠单抗注射液(施瑞立)销售额较上年同期稳步提升；另一方面本报告期公司乌司奴单抗注 射液(STARJEMZA)于美国上市销售，授权许可收入及销售收入增长。 ...

2、预计归属于母公司所有者扣除非经常性损益后的净利润为-38,000.00 万元 到-49,000.00 万元，将减少亏损 6,561.09 万元至 17,561.09 万元。 证券代码：688177 证券简称：百奥泰 公告编号：2026-006 百奥泰生物制药股份有限公司 2025 年年度业绩预亏公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 1、经财务部门初步测算，百奥泰生物制药股份有限公司（以下简称"公司"） 预计 2025 年度实现归属于母公司所有者的净利润与上年同期相比，将减少亏损， 实现归属于母公司所有者的净利润为-28,000.00 万元到-39,000.00 万元，减少亏 损 12,030.38 万元到 23,030.38 万元。 （三）本次业绩预告未经注册会计师审计。 二、上年同期业绩情况 （一）利润总额：-51,030.38 万元。归属于母公司所有者的净利润为-51,0 ...

Core Viewpoint - The company expects to achieve revenue of 900 to 970 million yuan in 2025, indicating an increase of 157 to 227 million yuan compared to the previous year [1] Financial Performance - The net profit attributable to the parent company is projected to be between -280 to -390 million yuan, representing a reduction in losses by 120 to 230 million yuan [1] - The non-GAAP net profit is expected to range from -380 to -490 million yuan, which will decrease losses by 66 to 176 million yuan [1] Market Expansion - The reduction in losses is attributed to the company's market expansion efforts, including increased sales of Adalimumab and Tocilizumab [1] - The launch of Ustekinumab in the United States and growth in licensing and sales revenue also contributed to the improved financial outlook [1]